Group 1 - The core viewpoint of the news highlights the recent performance of Yonghe Medical, which saw a stock price increase of 9.38% on May 9, closing at 1.05 HKD per share, while the Hang Seng Index rose by 0.4% to 22867.74 points [1] - Over the past month, Yonghe Medical has experienced a cumulative increase of 1.05%, and a year-to-date increase of 6.67%, which is lower than the Hang Seng Index's increase of 13.54% [2] - Financial data shows that as of December 31, 2024, Yonghe Medical achieved total revenue of 1.804 billion RMB, a year-on-year increase of 1.53%, and a net profit attributable to shareholders of -226 million RMB, a year-on-year increase of 58.58%, with a gross margin of 60.08% and a debt-to-asset ratio of 58.65% [2] Group 2 - Currently, there are no institutional investment ratings for Yonghe Medical, and the average price-to-earnings (P/E) ratio for the healthcare equipment and services industry is -21.69 times, with a median of 0.28 times [3] - Yonghe Medical's P/E ratio stands at -2.06 times, ranking 90th in the industry, compared to other companies such as Giant Medical Holdings at 0.19 times and Jingjiu Health at 0.38 times [3] - Yonghe Medical Group Limited is a medical group providing one-stop hair medical services, focusing on the hair medical service market since 2005, and has established a brand matrix including "Yonghe Medical," "Yonghe Hair Transplant," and others, with 72 hair transplant medical institutions across 68 cities in China as of June 30, 2023 [3]
雍禾医疗（02279.HK）5月9日收盘上涨9.38%，成交57.54万港元